Company: WHWK
Filing Date: 2025-02-19
Form Type: DEFA14A
Source: 0001193125-25-029692
Chunk: 1

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-02-19
Form: DEFA14A
Chunk 1
---
-generation oncology therapies and create long-term value for stockholders. We believe we will have an enhanced pipeline of leading ADC assets and the capital we need to unlock the potential of our portfolio. We have the support and guidance of credible biotech investors and an augmented Board with the skills and experience necessary to oversee our strategic plan. The Board and I therefore strongly recommend this series of transactions as the best way to transform Aadi and maximize value for its shareholders. Notably, upon announcement of these transactions in December 2024, our stock price rose 46% in the first day of trading. To keep this momentum, we now need stockholders to vote in support of the transactions. Please do so by voting online today using the instructions on the enclosed proxy card. Sincerely, /s/ David Lennon, Ph.D. David J. Lennon Ph.D. President & Chief Executive Officer, On behalf of the Aadi Bioscience Board of Directors Aadi Bioscience, Inc. • Two Headquarters Plaza, Morristown, NJ, 07960, USA • www.aadibio.com

…

Forward-Looking Statements

This communication contains
certain forward-looking statements regarding the business of Aadi Bioscience that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the
Company’s current beliefs and expectations and may include, but are not limited to, statements relating to: the Company’s positioning to develop next-generation oncology therapies and creation of long-term value for stockholders; the value
of the Company’s pipeline and potential of the ADC assets; and the amount of capital required to develop the ADC assets and the Company’s portfolio. Actual results could differ materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which include, without limitation, risks associated with (i) the risk that the conditions to the closing of the proposed sale of FYARRO or the PIPE financing are not satisfied, including
the failure to timely obtain stockholder approval for the transactions, if at all; (ii) uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of Kaken and Aadi to consummate the proposed sale of
FYARRO; (iii) risks related to Aadi’s ability to manage its operating expenses and its expenses associated with the proposed transactions pending the closing; (iv) risks related to the failure or delay in obtaining required approvals
from